Mich. Drug Companies Now Less Immune Under Tort Reform
Law360, New York (February 11, 2014, 5:20 PM EST) -- In a decision of critical importance for any pharmaceutical or medical device company doing business in Michigan, on Jan. 21, 2014, the U.S. Court of Appeals for the Sixth Circuit reversed the dismissal of a fentanyl patch lawsuit, ruling that manufacturers and sellers of "combination products" are not statutorily immune from liability under Michigan's Tort Reform statute. (Miller v. Mylan Inc., No. 12-2502 (6th Cir. Jan. 21, 2014)).
That statute, before now, provided drug companies with nearly absolute immunity from suit in Michigan, except in cases of fraud or bribery to secure federal approval:
In a product liability action against a...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!